Dana-Farber's Paolo Tarantino, MD, presented results from the RELIEVE study showing patients with metastatic breast cancer receiving trastuzumab deruxtecan fared best if they had HER2+ disease or stable HER2-low disease.
So we know that trust to theus or TDXT is antibio or conjugate approved for treating patients with metastatic her two positive or her two low breast cancer. But we have very little real world data with this agent. And also we don't know its activity in patients with changes in her two status. And this is why we conducted relief. That is um an effort that we had at Dana Fibre Cancer Institute together with Duke to look at the real world activity of TDXD and the the impact of her two changes in time. And we had 191 patients that receive TDXD in the real world of which two thirds had her two positive disease, one third at either her two low or even her 20 disease based on the latest biopsy. What we found is that the activity of TDXT was the highest in her two positive disease about 10 months of time to next treatment compared to seven months for her too low and approximately four months for her to zero. But most importantly, when we looked at differences in her two status between the primary tumor and the metastatic setting we found that patients that had her two low disease on both uh sites primary to metastatic setting. They had the time to next treatment on almost 10 months compared to only five months if they had changes from zero to low and only three months, if they have changes from low in the primary setting to zero in a metastatic setting, we also looked at activity of post TDXT treatment and it was quite short time for next treatment of about 3 to 4 months. Um depending on the type of her two positive status or her to lower zero. And finally, we conducted some correlative analysis and we found that patients with her B two hemizygous deletions and numerically shorter time to next treatment. And and also we conduct a biopsy analysis with DNA DX finding a difference in time to next treatment with TDXD depending on her two addiction calculated on this liquid biopsy. So, in general, we see that the her two status can impact the efficacy of TDXD and also dynamic her two status can do so. And we aim in the future to expand this effort and also conduct more correlative analysis.
